The market volatility in the last 18 months has made it difficult for public biopharmaceutical companies to maintain their valuations and raise new capital. Hear how several public companies faced data that was disappointing to investors and raised money anyway. Panelists will discuss what they did to avoid a cash crunch and the mechanics involved in pursuing and securing secondary offerings as well as their thinking around strategy, timing, and investor engagement. Rather than a deep dive on ’finance 101,” this will be a high level, lively discussion about the factors under consideration leading up to financing, what terms and conditions were acceptable and optimal, and overall street receptivity. Panel members will also discuss investor sentiment over the last year, what was different about it, and approaches taken to overcome industry skepticism.